Overview
- Published in PNAS, the CNIO-led work targets the KRAS pathway at three nodes—KRAS, EGFR and STAT3—to prevent rapid resistance.
- The regimen combined daraxonrasib (a KRAS inhibitor), afatinib (an EGFR blocker) and SD36, an experimental STAT3 degrader.
- In patient-derived xenograft models, 16 of 18 mice were disease-free roughly 200 days after treatment with no significant toxicity reported.
- Genetically engineered mouse models also showed complete, durable tumor regressions, strengthening the preclinical signal across systems.
- Mariano Barbacid said advancing to trials will require optimizing components, securing regulatory clearance and raising about €30 million for a phase 1 study.